Ask a doctor or pharmacist before use if you are taking:

• Warfarin (blood-thinning medicine)
• Prescription antifungal or anti-yeast medicines
• Diazepam (anxiety medicine)
• Digoxin (heart medicine)
• Tacrolimus (immune system medicine)
• Atazanavir (medicine for HIV infection)

Prilosec OTC^® and Plavix^®: FDA Health Advisory Issued
A public health advisory issued by the FDA on November 17, 2009, recommends patients avoid the combination of omeprazole products (i.e., Prilosec Rx^®, Prilosec OTC^®, and generic/store-brand omeprazole) with clopidogrel, which is marketed as Plavix.

The FDA recommends patients avoid the combination of these two drugs because, according to data provided by the makers of Plavix, omeprazole may reduce the anti-clotting effect of Plavix. However, the FDA recognizes that when used individually, these products provide significant health benefits.

When used as directed, Prilosec OTC^® has a strong safety profile—millions of consumers have tried it since it became available over the counter in 2003. However, consistent with the FDA, we encourage our consumers to avoid the combination of omeprazole with Plavix. The FDA also has advised that patients using Plavix should consult with their healthcare provider if they are currently taking or considering taking omeprazole, including Prilosec OTC^®.

Consumers currently treating frequent heartburn with Prilosec OTC^® and who are NOT taking clopidogrel (Plavix) or other medications contraindicated on the Prilosec OTC^® label can continue using Prilosec OTC^® as directed, unless otherwise indicated by a healthcare professional.

Talk to a medical professional before you stop or start taking any medication or if you have additional questions.

Please refer to the FDA's official release with more information:
http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm190825.htm.

Plavix is a registered trademark of Sanofi-Aventis Corporation.